| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | EURM2 |
| Uniprot No | Q9TZZ2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 17-145aa |
| 氨基酸序列 | DQVDIKDCANHEIKKVMVPGCKGSEPCVIHRGTAFQLEAVFDANQNSNAAKIEIKATIDGVEIDVPGIDNNLCHFMKCPLVKGQEYDIKYTWNVPRIAPKSENVVVTVKLLGDNGVLACAIATHAKIRD |
| 预测分子量 | 18.1kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于EURM2重组蛋白的模拟参考文献(虚构内容，仅供示例参考)：
1. **标题**：*Structural Characterization and Functional Analysis of EURM2 Recombinant Protein*
**作者**：Smith, J. et al.
**摘要**：研究通过大肠杆菌表达系统纯化EURM2重组蛋白，利用X射线晶体学解析其三维结构，并发现其通过调节TGF-β信号通路参与细胞增殖调控。
2. **标题**：*EURM2 Recombinant Protein Attenuates Inflammatory Response in Murine Models*
**作者**：Lee, H. et al.
**摘要**：探讨EURM2重组蛋白在小鼠炎症模型中的作用，证明其通过抑制NF-κB通路降低促炎因子表达，为治疗自身免疫疾病提供潜在靶点。
3. **标题**：*Optimization of EURM2 Recombinant Protein Production in Yeast Expression Systems*
**作者**：Zhang, Y. et al.
**摘要**：通过优化毕赤酵母表达系统的培养条件和启动子序列，显著提高EURM2蛋白产量，并验证其生物活性与天然蛋白一致。
4. **标题**：*EURM2 Binds to EGFR and Modulates Cancer Cell Metastasis*
**作者**：Johnson, R. et al.
**摘要**：揭示EURM2重组蛋白与表皮生长因子受体(EGFR)的相互作用机制，体外实验表明其可抑制肺癌细胞迁移和侵袭能力。
(注：以上文献为假设性内容，实际研究中请通过学术数据库检索相关论文。)
**Background of EURM2 Recombinant Protein**
The EURM2 recombinant protein is a genetically engineered biomolecule designed for research and therapeutic applications. Derived from a specific protein of interest, its production involves cloning the target gene into an expression vector, followed by introduction into host systems like *E. coli*, yeast, or mammalian cells. This allows scalable production under controlled conditions. The "EURM2" designation likely reflects its functional or structural attributes, such as a modified epitope, receptor-binding domain, or fusion partner (e.g., His-tag for purification).
EURM2 is typically engineered to enhance stability, solubility, or functional activity compared to its native counterpart. Post-translational modifications (e.g., glycosylation) may be optimized depending on the host system, ensuring proper folding and biological relevance. Its applications span structural studies, *in vitro* assays, antibody development, and drug screening. For instance, in immunology, EURM2 might serve as an antigen to generate antibodies or study immune responses. In drug discovery, it could act as a target for small-molecule inhibitors or biologic therapies.
The development of EURM2 aligns with advances in recombinant technology, CRISPR-based gene editing, and bioinformatics-driven protein design. Rigorous quality controls, including SDS-PAGE, Western blotting, and functional assays, validate its purity and activity. As a research tool, EURM2 contributes to elucidating molecular pathways, disease mechanisms (e.g., cancer, infectious diseases), and therapeutic interventions. Its versatility underscores its importance in both academic and industrial biotechnological workflows.
×
